Wendy L. Dixon brings extensive experience in senior strategic leadership in both biopharma regulatory and commercialization to her role as CEO advisor. Dr. Dixon has been the President of Great Meadow Consulting, L.L.C., a life science consulting firm, since July 2009. Additionally, Dr. Dixon has been an advisor to the Mellon Group since August 2014 and was a Senior Advisor to The Monitor Group, now Deloitte Consulting LLP, a consulting firm, from November 2010 to January 2012. Dr. Dixon serves as a member of the board of directors for a number of biopharmaceutical companies, including bluebird bio Inc., Alkermes PLC, Incyte Corporation and Voyager Therapeutics, Inc. Dr. Dixon previously served on our board of directors from 2014-2020, and as Chair from 2016-2020. Dr. Dixon also served as chief marketing officer and president of Global Marketing for Bristol-Myers Squibb and as a member of the CEO’s Executive Committee from 2001 to 2009. She has had an over 30-year career in the pharmaceutical and biotechnology business, combining a technical background and experience in drug development and regulatory affairs with commercial responsibilities in building and leading organizations and launching and growing more than 20 pharmaceutical products. From 1996 to 2001, she was senior vice president, marketing at Merck and prior to that she held executive management positions at West Pharmaceuticals, Osteotech and Centocor, and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon received her B.Sc., M.Sc. and Ph.D. from the University of Cambridge (UK).

Jane V. Henderson brings extensive experience in senior financial leadership and healthcare investment banking to her role as CEO Advisor. Ms. Henderson currently serves as the Chief Financial Officer of Adagio Therapeutics. Previously, Ms. Henderson served as the Chief Financial Officer of Turnstone Biologics from July 2018 to December 2020. Before joining Turnstone Biologics, Ms. Henderson served as the Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc., a biopharmaceutical company, from January 2017 to July 2018. Prior to Voyager, Ms. Henderson served as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., a biopharmaceutical company, from February 2013 to November 2016, when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., from June 2010 to June 2012, when ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson also served as the Chief Financial Officer and Head of Business Development at Axerion Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. Ms. Henderson previously served on our Board of Directors from 2013-2021. In addition to her industry experience, Ms. Henderson’s extensive healthcare investment banking experience includes the execution of over 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University.

Chair of the Audit Committee
Member of the Compensation Committee

Daniel S. Lynch brings extensive experience in senior executive leadership to his role as a CEO advisor. Since 2005, Mr. Lynch has advised and served as executive chair or member of the board of directors for several life science companies, including on the board of directors of bluebird bio, Inc., Blueprint Medicines Corp., Surface Oncology, SpringWorks Therapeutics and Translate Bio. Previously, Mr. Lynch served on the board of directors of DNIB Unwind, Inc. (formerly BIND Therapeutics, Inc.) from 2012 until its acquisition by Pfizer Inc. Mr. Lynch previously served on our board of directors from 2013-2020, and as Chair from 2013-2016. Mr. Lynch has served as a venture partner at Third Rock Ventures, a venture capital firm, since May 2013 and as an entrepreneur-in residence from May 2011 to May 2013, and now serves as a senior advisor. Prior to that, Mr. Lynch served as the Chief Financial Officer and then the Chief Executive Officer of ImClone Systems Inc. As ImClone’s chief executive officer, he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. Mr. Lynch received a B.A. in Mathematics from Wesleyan University and a M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.

Louise Park Stejbach brings more than 30 years of biopharma commercialization and brand strategy experience to her role as commercial advisor.  Since 2008, Louise has advised on pre-launch and launch planning, market assessment and prioritization, target product profile development, and go-to-market plans for several pre-commercial and first commercial biotech firms as well as established biopharmaceutical companies, vaccine manufacturers, and other healthcare clients.  Prior to consulting, Ms. Stejbach spent 18 years at Merck where she developed deep experience in commercial (HCP, payer, patient) strategy and execution across many therapeutic categories and stages of the lifecycle and held US leadership roles as both the Vice President of Marketing for Diabetes and the Vice President of Osteoporosis Marketing and Specialty Sales.  Louise has an MBA (University of Chicago) and a BS in Chemical Engineering (University of Virginia).